Jupiter Neurosciences Prices $2M Offering of 7.14M Shares for CNS Pipeline
Jupiter Neurosciences priced a registered direct offering of 7,142,858 common shares to raise approximately $2.0 million, with closing expected May 21, 2026. The shares are issued under an effective Form S-3 shelf registration declared effective April 24, 2026, to fund its CNS disorder and neuroinflammation pipeline.
1. Registered Direct Offering Terms
Jupiter Neurosciences entered into a securities purchase agreement to sell 7,142,858 common shares in a registered direct offering, generating gross proceeds of $2.0 million. D. Boral Capital LLC is acting as exclusive placement agent and the closing is expected on or about May 21, 2026, subject to customary closing conditions under an effective Form S-3 shelf registration.
2. Pipeline Financing and Strategic Impact
Net proceeds from the offering will support the Company’s clinical-stage pipeline targeting central nervous system disorders and neuroinflammation. Funds are expected to advance the Phase IIa trial of JOTROL in Parkinson’s disease, integrate the newly acquired ALA-002 rights, and cover general corporate purposes.